Centene Corp vs MobilEye Global Inc — how do they compare? Centene Corp trades at $66.47 (market cap $33.93B), while MobilEye Global Inc trades at $9.46 (market cap $8.50B). The key difference: Centene Corp is far larger — about 4× MobilEye Global Inc's market cap, and Centene Corp is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| CNC | MBLY | |
|---|---|---|
Market Cap | $33.93B | $8.50B |
Sector | Health | Technology |
52-Week High | $68.72 | $16.27 |
52-Week Low | $25.21 | $6.56 |
Enterprise Value | $26.56B | $7.15B |
Signals from Pluang's Aura AI — not financial advice
Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.
Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.
MBLY trades at $9.75, up 2.09% today, with a bullish technical signal and strong analyst support (57.69% buy ratings). The company reported Q1 2026 EPS of $0.12, beating expectations, but faces profitability challenges with a net income margin of -203.97% for 2026. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it beyond traditional ADAS supply.
The outlook hinges on MBLY's execution of its robotaxi initiative, offering growth potential but carrying significant execution and competitive risks. While near-term fundamentals show losses, the stock's current price near the consensus target of $10.50 suggests limited upside unless profitability improves or new ventures accelerate. Investors should weigh the high-risk, high-reward profile amid volatile earnings.
Trailing returns across standard periods
Latest headlines on both assets
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →